NextCure, Inc. (NXTC) · Nov 20, 2026 · Delisting
Nasdaq deficiency — $5.503M equity vs $10.0M minimum; compliance-plan deadline January 4, 2027
NextCure’s delisting notice has no immediate trading impact, but the Avere merger must close before January 4 to address the equity shortfall.
NextCure is no longer primarily a clinical-stage oncology developer: it has wound down much of its legacy pipeline and is using the proposed Avere merger to pivot toward Avere’s oral IL-23 inflammatory-disease programs. The latest quarterly filing had already disclosed that equity was below Nasdaq’s minimum, so this 8-K formalizes a known vulnerability rather than creating a surprise.
The filing adds a real listing risk, but not an immediate delisting. Nasdaq says NextCure’s stockholders’ equity was $5.503 million against a $10.0 million requirement, and the company failed the alternative market-value and assets/revenue tests.
| Measure (Item 3.01) | As reported | Requirement | Deadline |
|---|---|---|---|
| Stockholders’ equity | $5.503M | $10.0M minimum | — |
| Compliance-plan window | 45 days | — | January 4, 2027 |
The merger is now more than a strategic pivot—it is the practical compliance solution. NextCure expects the Avere transaction to close in mid-December, before the January 4 grace-period deadline, and says completion would likely restore compliance. But that outcome remains conditional on stockholder approval and other closing requirements; if the merger slips, NextCure must submit a remediation plan and still cannot assure Nasdaq compliance.
The immediate damage is contained, while the dependency is clearer. Trading continues on Nasdaq for now, so this is not a present delisting event. But it exposes how little standalone balance-sheet flexibility remains and makes timely completion of the already-public merger more important to the company’s near-term continuity. 〔0〕
Bottom line: This is a modest negative development, not a change in the merger thesis: the equity deficiency was already known, but Nasdaq has now put a firm compliance clock around it. The Avere closing is effectively the company’s near-term answer to the listing problem.
NextCure stockholder vote on Avere merger, December 9
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!